Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia Leukemia (2005) A family has recently been described in whom three members affected by acute myeloid leukaemia (AML) carried germline heterozygous mutations in CCAAT enhancer-binding proteinalpha (CEBPA), the gene encoding the granulocyte differentiation factor C/EBPa. 1 The transcription factor C/EBPa is a key regulator of early myeloid differentiation, regulating a number of granulocyte-specific genes and inducing granulocytic development of bipotential myeloid progenitors by activation of target gene promoters. 2 C/EBPa consists of N-terminal transactivating domains (TAD1 and TAD2) and a C-terminal basic and leucinezipper region necessary for specific DNA sequence binding and homo-or heterodimerization, respectively. 2 Here, we report the clinical and molecular features of a second family in which a germline mutation in CEPBA caused AML.
The family, in which four members had documented evidence of developing AML was originally reported in 1998 (Figure 1 ). 3 Briefly, individual III:1 presented at 34 years of age with AML. Individual IV:2 presented at age 25 years with AML M4 with eosinophilia with cytogenetic analysis revealing an abnormal clone 46XY,del(6)(q21) in 5/16 cells. Individual IV:4 presented at age 24 years with AML M1. No clonal cytogenetic abnormality was detected. Individual V:1 presented at age 4 years with AML M1. Cytogenetic analysis of individual V:1 at presentation was normal but on relapse the clonal abnormality 47,XY, þ 8 was observed, with clonal evolution to 47,XY, þ 8, þ 21 at subsequent relapse. Individuals IV:2 and V:1 remain well 18 and 14 years from original diagnosis of AML, respectively, despite experiencing one or more relapses. Individual IV:4 remains well in first remission 11 years from original diagnosis of AML. He has been shown to have a normal 46,XY karyotype. All members of the family (Figure 1 ) are white Caucasians and there is no evidence of consanguinity. We have previously excluded involvement of Fanconi, mutations in TP53 and RUNX1 and linkage to 16q21-23.2 as a cause of AML in the family. 3, 4 Samples of mononuclear-cell-enriched peripheral blood samples were obtained at diagnosis from individuals IV:2 and IV:4. Peripheral blood samples for germline mutation analysis were obtained from III:2 and IV:3 and from individuals IV:2, IV:4 and V:1 during remission. DNA was extracted using a routine salt-precipitation methodology.
The complete coding sequence of CEBPA (referenced to GenBank accession Y11525) was screened in individuals III:2, IV2, IV:3, IV:4 and V:1 as a series of overlapping PCR fragments. PCR primers were designed by use of Primer 3 software (http://www.broad.mit.edu/cgi-bin/primer/primer3_www.cgi). All primer sequences and PCR conditions are available upon request. Amplified PCR products were purified (Qiagen Inc., Valencia, CA, USA) and bidirectionally sequenced using BigDye Terminator chemistry implemented on an ABI Prism 3100 sequencer. Sequences were aligned and compared to consensus Using DNA extracted from venous blood samples obtained during remission, the affected family members IV:2, IV:4 and V:1 were found to harbour an out-of-frame germline mutation involving insertion of a cytosine residue at nucleotide 217 of CEBPA (217insC) (Figure 2a ). CEBPA can be translated from the first AUG start codon encoding the 42-kDa normal isoform and also from a second internal AUG (nt 504-506) encoding a 30-kDa alternative isoform, which has lost the first 119 amino acids including the TAD1 domain. The shorter 30-kDa protein has a dominant negative effect on the 42-kDa wild-type (wt) C/EBPa by inhibiting DNA binding and transactivation by wtC/EBPa.
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The germline mutation 217insC identified in our family creates a frameshift leading to truncation of the 42-kDa protein at amino acid 106. Similar N-terminal mutations that disrupt the C/EBPa reading frame have been shown to result in enhanced translation of the 30-kDa isoform causing loss of wtC/EBPa function by the deregulation of target gene expression leading to a failure to induce granulocytic differentiation. 5 Direct sequencing of the tumour-enriched diagnostic samples obtained from individuals IV:2 and IV:4 revealed additional inframe insertion/deletion C-terminal somatic mutations. The sample from individual IV:2 carried a seven base pair deletion (GAGACGC) and insertion of 10 bases (CTGGAGGCCA) at position 1071 (E308_Q310delinsLEAK) (Figure 2b ). The sample from individual IV:4 harboured an insertion of GAC at nucleotide 1071 which resulted in insertion of glutamic acid at position 308 (E308dup) of CEBPA. Both mutations are predicted to prevent dimerization of C/EBPa because they disrupt the bZIP domain and therefore result in loss of function of the normal allele.
Intriguing, the site and type of mutations identified in the affected individuals in the family we report are almost identical to those in the AML family published by Smith et al. Specifically, the germline mutation in the family they reported was a truncating out-of frame N-terminal 212delC mutation; and the somatic mutation in one diagnostic sample was a 36-bp inframe duplication of C-terminal nucleotides 1050-1085 resulting in an internal tandem duplication of amino acids 301-312 (Figure 2b) , thereby disrupting the bZIP dimerization domain.
Somatic mutations in CEBPA are detectable in around 9% of AML primarily in patients with normal cytogenetics and the FAB subtypes M1, M2 and M4. 6 It is noteworthy that the affected individuals in the family reported by Smith and co-workers had either FAB type M1 or M2 disease. 6 Studies of sporadic AML cases have demonstrated that mutation of CEBPA is an independent marker of favourable prognosis. 1 Accepting the caveat of ascertainment bias, this observation provides one possible explanation for the less-aggressive clinical course seen in affected individuals in both our family and the family reported by Smith et al. 1 The early onset of AML in the families' contrasts markedly with age of onset of sporadic disease associated with mutations (median ages being 24 and 47 years, 6 respectively) reflecting predisposition.
The observation that germline mutations in CEBPA predispose to AML indicates that mutations in this gene contributing to the loss of function of the expressed protein in early myeloid differentiation are sufficient to cause myeloid leukaemia. Moreover, the finding of somatic mutations in CEBPA in tumour samples suggests that inactivation of another gene is not necessary for leukemogenesis. , and mouse #20 (T20) tumors, wild-type tail (t); pX is phiX ladder, and w is water control. Lower panel: control PCR (p53). PCR products were subcloned and sequenced. In all, 10 out of 10 clones showed identical DSP2.9-Jh3 rearrangement (shown at the bottom). (d) Clonality by Southern blot. DNA from mouse #3 (SP ¼ spleen, LN ¼ lymph node, t ¼ tail) was digested with the indicated enzymes (and SpeI, not shown) and hybridized with a Jh4 intron probe to detect IgH rearrangements. Note the dimmer signal intensity of the DSP2.9-Jh3 predicted rearrangement (dotted arrow) compared to the rearranged second allele (filled arrow). No light-chain gene rearrangement was detected (data not shown).
